Skip to content Skip to footer
Subscribe Now
NEWS

BioAtla and GATC Health Announce $40M SPV Transaction to Advance Ozuriftamab Vedotin into P-III Study for 2L+ OPSCC

Shots: BioAtla and GATC Health announce  into a $40M special purpose vehicle (SPV) transaction to advance ozuriftamab vedotin (Oz-V), a CAB-ROR2-ADC, into a registrational P-III study for 2L+ oropharyngeal squamous cell carcinoma (OPSCC) Under the agreement, BioAtla will receive $5M upfront to support operations and P-III study execution, with the remaining $35M expected to close…
January 2, 2026

Read more

NEWS

Shanghai Henlius Receives the US FDA IND Clearance for HLX18 (Biosimilar, Opdivo)  

Shots:  The US FDA has granted IND clearance to HLX18 (nivolumab), a biosimilar version of Opdivo, for the treatment of certain resected solid tumors   Novolumab is an mAb targeting PD-1 to enhance anti-tumor immune responses and is approved worldwide for cancers, including melanoma, mesothelioma, head and neck, and urothelial carcinoma   HLX17 (pembrolizumab biosimilar) and HLX13 (ipilimumab biosimilar) have entered worldwide multicenter P-I…
December 19, 2025

Read more

Merus
NEWS

Genmab to Acquire Merus for ~$8B

Shots: Genmab has entered into a transaction agreement to acquire Merus, incl. its lead asset petosemtamab, expanding its late-stage pipeline & accelerating Genmab’s shift to a wholly owned model As per the deal, Genmab will acquire Merus for $97 per share in an all-cash transaction, representing the deal value of ~$8B, with closing expected in the…
September 29, 2025

Read more

NEWS

Rakuten Medical Commences Global P-III (ECLIPSE) Study of ASP-1929 Plus Keytruda as a 1L Treatment of Recurrent Head and Neck Cancer

Shots: The company has begun P-III (ECLIPSE) trial of ASP-1929 (photoimmunotherapy) + Keytruda for HNSCC, with first patient treated at a site across the US. Recruitment is underway in Japan, Taiwan & other regions This global study aims at assessing safety & efficacy of ASP-1929 + Keytruda vs Keytruda-based SoC as a 1L treatment…
January 24, 2025

Read more

PharmaShots Interview Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy
VIEWPOINTS

PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

Shots:  Laurent spoke about the study design of its nanoparticle therapy to enhance the cancer-killing effect of radiation, which was presented at ASCO 2022 Laurent also highlighted how this nanoparticle therapy can be a potential radio enhancer in various tumor types and across lines of therapy The interview summarizes Nanobiotix’s vision to advance nanoparticles across…
August 10, 2022

Read more